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Background: Airway mucus hypersecretion is an important problem in chronic respiratory 
diseases including bronchial asthma. Chlamydophila pneumoniae is recently confirmed to be 
a pathogen in bronchial asthma, but the relationship between C. pneumoniae and mucus 
hypersecretion is uncertain. In this study, we examined whether C. pneumoniae induces 
MUC5AC mucin in airway epithelial cells. We also examined the effects of macrolide and 
ketolide antibiotics on the C. pneumoniae-induced mucus production.  
Methods: MUC5AC production in bronchial epithelial cells after stimulation with C. 
pneumoniae was analyzed by ELISA and quantitative RT-PCR. NFB and phosphorylated 
ERK were also analyzed. For inhibition study, cells were pretreated with azithromycin, 
clarithromycin and telithromycin before stimulation.  
Results: C. pneumoniae dose-dependently induced MUC5AC production and gene expression. 
The ERK-NF-B pathway was involved in C. pneumoniae-induced MUC5AC production. 
Macrolides and ketolides dose-dependently reduced C. pneumoniae-induced MUC5AC 
production. However, azithromycin was apparently less effective than the other antibiotics. 
Clarithromycin and telithromycin, but not azithromycin, reduced NF-B activation. 
Conclusions: Clarithromycin and telithromycin were thought to interfere with the signal 
pathways between ERK and NF-B. These results suggest that airway mucus hypersecretion 
is one of the mechanisms of Chlamydophila pneumoniae-induced bronchial asthma, and that 
macrolide and ketolide antibiotics represent a novel therapeutic intervention in these patients. 
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1. Introduction 
 
 Airway mucus coats the surface of the respiratory tract, acts as a protective barrier against 
pathogens and foreign irritants and provides the setting for the innate immune system. 
However, excessive mucus production contributes to restriction of the airway and insufficient 
gas exchange. This mucus hypersecretion is observed in various chronic airway diseases, 
such as diffuse panbronchiolitis (DPB), cystic fibrosis, chronic obstructive pulmonary 
diseases and bronchial asthma. The control of mucus hypersecretion may thus contribute to 
the treatment of these diseases.  
More than 20 mucin genes have been identified in humans, and they are generally 
classified into membrane-associated and gel-forming mucins [1, 2]. The gel-forming mucins 
are secreted mucins that provide the viscoelastic properties of the extracellular mucus layer. 
MUC2, MUC5AC, MUC5B, MUC6 and MUC19 belong to this family, and MUC5AC is 
strongly expressed in the lung [3]. MUC5AC is up-regulated by various bacterial stimulants. 
  Bronchial asthma is the most common chronic respiratory disease in the world. It is well 
known that airway inflammation is a key part of the pathogeneses of bronchial asthma. 
Airway inflammation is characterized by mucus hypersecretion and immigration of 
inflammatory cells into the airway lumen. Mucus hypersecretion leads air-flow restriction or 
obstruction. Pathological findings in the lung of fatal asthma patients have shown increased 
mucus gland and airway lumen area occupied by mucus [4]. These mucus plugs consist 
primarily of mucins [5], and MUC5AC and MUC5B are the major components of mucins 
[6].  
  Chlamydophila pneumoniae is one of the causes of pneumonia, and it is probably 
associated with bronchial asthma. C. pneumoniae infection is observed more frequently in 
stable asthma patients than in healthy controls [7]. It is thought that exacerbation of asthma 
can be also triggered by C. pneumoniae [8]. Patients with asthma exhibit excess mucin 
production in the airway; however, it is uncertain whether C. pneumoniae affects the 
production of mucins in airway epithelium. 
  It is gradually being accepted that macrolide antibiotics not only possess antibacterial 
activity, but also exert immunomodulatory effects. Macrolides have been shown to improve 
the survival rate of DPB patients [9]. Clarithromycin reduced the volume of sputum in 
patients with chronic lower airway diseases [10]. This efficacy is not considered to depend on 
bactericidal activity, as macrolides have no bactericidal potential against the Pseudomonas 
aeruginosa typically isolated from chronic airway infectious disease patients. The 
suppression of mucus hypersecretion is seen with erythromycin, clarithromycin and 
azithromycin in vivo and in vitro [11-12]. Telithromycin is a novel ketolide antibiotic that 
structurally resembles macrolides. It has also been reported that telithromycin has similar 
immunomodulatory effects as macrolides [13].  
Because C. pneumoniae is now considered to be a pathogen involved in asthma, we 
hypothesized that C. pneumoniae up-regulates MUC5AC in airway epithelial cells. We also 
investigated the effects of macrolides and ketolides on the MUC5AC production induced by 
C. pneumoniae. 
 
2. Materials and Methods 
 
2.1. Materials 
  Mouse MUC5AC monoclonal antibody (clone 45M1) was obtained from MONOSAN 
(Uden, Netherlands). Goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary 
antibody was obtained from Bio-Rad (Hercules, CA). Rabbit anti-extracellular 
signal-regulated kinase (ERK) and phosphor-ERK antibodies were obtained from Cell 
Signaling Technology (Danvers, MA). Goat anti-rabbit HRP-conjugated secondary antibody 
was obtained from GE Healthcare (Chalfont St. Giles, United Kingdom). Caffeic acid 
phenethyl ester (CAPE), PD98059 and U0126 were obtained from Calbiochem (San Diego, 
CA).  
2.2. Preparation of C. pneumoniae antigen   
The C. pneumoniae KK-pn15 strain, which was isolated in our laboratory from a patient 
with acute pharyngitis, was used as the antigen [14]. The C. pneumoniae strain was grown in 
a HEp-2 cell culture and harvested on day 3 post-inoculation. The elementary bodies (EBs) of 
the KK-pn15 strain were purified by a method as described previously [15]. At 72 h 
post-inoculation, infected HEp-2 cells were collected in a sucrose-phosphate-glutamate 
solution (SPG; sucrose 7.5%, KH2PO4 0.052%, Na2HPO4.2 H2O 0.1529%, glutamic acid 
0.072%) and homogenized with a Teflon homogenizer. After a brief centrifugation at 900 g 
for 10 min at room temperature to remove cell debris, the supernatant obtained was layered 
onto a two-layer cushion (bottom layer, 50% wt/vol sucrose solution; top layer, 30% vol/vol 
Urografin [3,5-diacetamido-2,4,6-triisobenzoic acid; Schering AG, Berlin/Bergkamen, 
Germany] in 30 mM Tris-HCl buffer [pH 7.3]) and then centrifuged at 8,000 g for 60 min at 
4°C with an RPS-25 swing rotor (Hitachi, Tokyo). The precipitate and the turbid bottom layer 
were suspended together with SPG and then treated with DNAse and RNAse (final 
concentration; 20 μg/mL each) for 30 min at 37°C. The suspension was layered onto a 
continuous Urografin gradient column (40 to 52% vol/vol) and centrifuged at 8,000 g for 60 
min at 4°C. Two distinct bands were formed in the gradient column. The presence of a 
number of EBs was confirmed in the lower band by electron microscopy. After washing with 
SPG, the EBs were suspended in SPG and stored at -80°C until required. 
2.3. C. pneumoniae quantification 
  For DNA extraction, C. pneumoniae EBs were suspended in lysis buffer (2 mM Tris-HCl 
[pH 8.3], 10 mM KCl, 0.05 mM MgCl2, 0.5% Triton X-100 and 0.5% Tween20) and 200 
g/ml proteinase K (Sigma, St. Louis, MO). Samples were digested at 55°C for 60 min, 
followed by 100°C for 10 min, and were then used as DNA extracts. C. pneumoniae was 
quantified by real-time TaqMan PCR targeting the ompA gene [16]. Templates were amplified 
with using a LightCycler system (Roche Diagnostics, Mannheim, Germany). 
2.4. Cell culture 
  NCI-H292 cells were cultured in RPMI-1640 medium with 10% FBS, penicillin (100 
U/ml) and streptomycin (100 g/ml). Cells were grown at 37°C with 5% CO2 and were 
subcultured twice weekly. When the cells reached confluence, cells were serum-starved for 
24 h and then stimulated with C. pneumoniae. For inhibition study, cells were pre-treated 
with macrolides or signal transduction inhibitors for 30 min before stimulation. As a control, 
cells were incubated medium alone. 
2.5. ELISA 
  NCI-H292 cells were cultured in 12-well plates and MUC5AC protein was measured by 
enzyme-linked immunosorbent assay (ELISA) [12]. After stimulation for 24 h, culture 
medium was kept as the supernatant. Cells were then washed with cold PBS and lysed with 
lysis buffer (20 mM Tris-HCl [pH 8.0], 133 mM NaCl, 1% NP-40 and 10% glycerol). The 
preparation was then cleared by centrifugation and the supernatant was saved as the cell 
lysate. Protein concentrations of the cell lysate were measured. Samples were stored at -80°C 
until use. Aliquots of supernatant and equal amounts of protein in the cell lysate were 
incubated at 40°C in a 96-well plate until dry. Plates were blocked with 2% bovine serum 
albumin for 1 h at room temperature, and incubated with MUC5AC antibody diluted in PBS 
containing 0.05% Tween 20 for 1 h. Secondary antibody was dispensed into each well for 1 h. 
Color was developed with 3,3’,5,5’-tetramethylbenzidine-peroxydase solution, and the 
reaction was stopped by adding 2 N H2SO4. Absorbance was read at 450 nm.  
2.6. Real-time quantitative RT-PCR 
  NCI-H292 cells were cultured in 6-well plates and stimulated for 8 h. Total RNA was 
extracted using QuickGene-Mini80 and QuickGene RNA cultured cell kits (FUJIFILM co., 
Tokyo, Japan) according to the manufacturer’s instructions. Total RNA (1 g) was reverse 
transcribed into cDNA using oligo(dT) primers and SuperScript III reverse transcriptase 
(Invitrogen, Carlsbad, CA), and were then treated with RNaseH. To quantify the expression 
of the MUC5AC gene, primers and Taqman probes were designed and used as reported 
previously (Forward primer, 5’-CAGCCACGTCCCCTTCAATA-3’; Reverse primer, 
5’-ACCGCATTTGGGCATCC-3’; Taqman probe, 
5’-6-FAM-CCACCTCCGAGCCCGTCACTGAG-TAMRA-3’) [17]. MUC5AC was 
amplified for 40 cycles (15 s at 95°C, and 30 s at 60°C) using a LightCycler system. To 
normalize MUC5AC expression, human porphobilinogen deaminase (hPBGD) was also 
measured using an hPBGD primer set (Roche Diagnostics GmbH, Mannheim, Germany) 
according to the manufacturer’s instructions. Data was presented as a ratio of hPBGD. 
2.7. NF-B transcription factor assay 
  Cells cultured in 6-cm dishes were harvested and nuclear extracts from cells were obtained 
using a nuclear/cytosol fractionation kit (BioVision, Lyon, France) according to the 
manufacturer’s protocol. Activities of p65 were investigated using an NF-B transcription 
factor assay kit (Upstate, Temecula, CA) according to the manufacturer’s instructions. Briefly, 
10 g of samples from untreated or treated cells and capture probe, double-stranded 
biotinylated oligonucleotides containing the consensus sequence for binding NF-B, were 
added to a streptavidin-coated 96-well plate. After incubation, bound p65 was detected using 
a primary anti-p65 antibody. The plate was incubated with secondary antibody, a 
chromogenic substrate was added to the cells, and the absorbance of each sample was read 
using a microplate reader. 
2.8. Western blot analysis 
  Cells were harvested after treatment, and were washed and homogenized at 4°C in lysis 
buffer (0.1% sodium dodecyl sulfate [SDS], 1% Igepal CA-630 and 0.5% sodium 
deoxycholate). Cell lysates (20-50 g) were resolved by electrophoresis on a 12.5% 
polyacrylamide gel, and were transferred to a polyvinylidine difluoride membrane. After 
blocking the membrane in 10% FBS and 0.1% Tween-20 in Tris-buffered saline for 1 h at 
room temperature, blots were hybridized overnight at 4°C with primary antibodies. After 
hybridization with secondary antibody, the immunocomplexes were visualized using an ECL 
Western blotting detection system (GE Healthcare, Chalfont St. Giles, United Kingdom).  
2.9. Statistical analysis 
 All data were expressed as means and standard deviation (SD). Fig. 2C and 2D were 
analyzed by unpaired t-test. In other examinations, one-way analysis of variance was used to 
determine statistically significant differences between groups. Dunnett’s test was used to 
confirm differences as compared to the control group. Differences were considered to be 




3.1. Preparation of C. pneumoniae 
  In order to exclude the antibacterial effects of drugs, we used inactivated C. pneumoniae 
EBs. We confirmed that these EBs lost their infectivity because no inclusion body was 
observed in purified EB-treated HEp-2 cells (data not shown). The number of C. pneumoniae 
used throughout this study was analyzed by real-time PCR and the mean concentration was 
6.55 ± 0.50 (SD) log10 copies per 10 g (n = 6). We used C. pneumoniae at several protein 
concentrations, and diluted C. pneumoniae correlated well with the quantitative results for the 
C. pneumoniae ompA gene (data not shown). 
 
3.2. C. pneumoniae induces MUC5AC protein production and gene expression 
  In order to determine whether C. pneumoniae protein induces production of MUC5AC in 
NCI-H292 cells, we evaluated MUC5AC protein by ELISA and gene expression by 
quantitative RT-PCR. C. pneumoniae dose-dependently increased MUC5AC production (Fig. 
1A and 1B) after 24 hours of stimulation. At the mRNA level, C. pneumoniae 
dose-dependently up-regulated MUC5AC gene expression after 8 hours of stimulation with a 
significant difference at 10 g/ml (Fig. 1C). For subsequent experiments, we thus used C. 
pneumoniae at a concentration of 10 g/ml. 
 
3.3. C. pneumoniae activates p65 and p50 involved in MUC5AC production 
NF-B is known to be involved in MUC5AC gene expression. To study the involvement of 
NF-B, we examined the activity of p65 and p50, major subunits of NF-B, after C. 
pneumoniae-stimulation. The activity of p65 rose significantly after 20 min, and continued to 
rise until it peaked at 60 min (Fig. 2A). p50 was also activated after stimulation, with peak 
activity seen at 40 min (Fig. 2B). Furthermore, in order to determine whether NF-B is 
involved in the production of MUC5AC, we evaluated MUC5AC protein using a specific 
NF-B inhibitor, CAPE. CAPE (10 M) decreased the levels of C. pneumoniae-induced 
MUC5AC in the supernatant by 28% (Fig. 2C, p = 0.050) and in the cell lysate by 72 % (Fig. 
2D, p = 0.043).  
 
3.4. C. pneumoniae phosphorylates ERK 
  Mitogen-activated protein kinases (MAPKs) are important signals related to MUC5AC 
production. We focused on ERK and examined the time course of phosphorylation by 
Western blotting (Fig. 3A). Phosphorylated ERK band was not seen at the beginning of 
stimulation, but appeared after 20 min. Phosphorylation of ERK remained at similar levels 
for 60 min. Moreover, PD98059 (50 M) and U0126 (10 M), ERK inhibitors, strongly 
suppressed the production of MUC5AC (Fig. 3B and 3C). 
 
3.5. Macrolide antibiotics suppress C. pneumoniae-induced MUC5AC production  
We examined the effects of azithromycin, clarithromycin and telithromycin on C. 
pneumoniae-induced MUC5AC production. To eliminate the effects of antibiotic against C. 
pneumoniae, we pretreated cells with macrolide or ketolide antibiotics for 30 min before 
stimulation. Azithromycin dose-dependently reduced C. pneumoniae-induced MUC5AC 
production (Fig. 4A and 4B). Clarithromycin and telithromycin dose-dependently reduced C. 
pneumoniae-induced MUC5AC production with a significant difference seen at 50 g/ml 
(Fig. 4C-4F). Based on these results, we analyzed the inhibitory effects of macrolide 
antibiotics at a concentration of 50 g/ml. 
 
3.6. Macrolide antibiotics suppress C. pneumoniae-induced MUC5AC gene 
expression 
  We also examined the inhibitory effects of macrolides at the mRNA level. After 
pre-treatment with macrolide antibiotics, cells were treated with C. pneumoniae for 8 h. 
Macrolide antibiotics reduced C. pneumoniae-induced MUC5AC gene expression to around 
the same levels as the control, with significant differences seen vs. stimulation alone (Fig. 5). 
 
3.7. Clarithromycin and telithromycin, but not azithromycin suppress C. 
pneumoniae-induced NF-B activation. 
  After pre-treatment with macrolides or ketolides for 30 min, cells were then treated with C. 
pneumoniae for 60 min. C. pneumoniae-induced p65 activation was significantly suppressed 
by clarithromycin and telithromycin but not azithromycin (Fig. 6A). Activated p50 was 
suppressed to baseline levels only after treatment with telithromycin (Fig. 6B). 
 
3.8. Macrolide antibiotics do not down-regulate C. pneumoniae-induced 
phospho-ERK 
  In order to investigate the effects of macrolides and ketolides on MAPK levels, cells 
pre-treated with macrolides or ketolides were stimulated with C. pneumoniae for 20 min. 
After that, phosphorylation levels of ERK were detected by Western blotting. These drugs did 




The present study demonstrates that C. pneumoniae protein increases mucus production, 
and that C. pneumoniae-induced mucus production can be suppressed by macrolide and 
ketolide antibiotics. This indicates a possible therapeutic approach to treat bronchial asthma. 
Airway mucus hypersecretion is a pathologic feature seen in obstructive lung diseases. 
MUC5AC, the major core protein of mucin, is up-regulated by various stimulants, including 
air pollutants [18], inflammatory mediators [19], cytokines [20] and bacterial components 
related to chronic airway diseases [12, 21]. In asthma patients, the airway mucus consists 
primarily of MUC5AC [6]. 
The relationship between bronchial asthma and pathogenic organisms has recently 
described in various studies. Mycoplasma pneumoniae has been shown to have an association 
with asthma [22]. M. pneumoniae induces MUC5AC production in human lung epithelial cell 
lines and in airway epithelial cells isolated from asthmatic patients [23]. Rhinovirus infection 
related to exacerbation of asthma increases MUC5AC and total mucin concentration in 
human tracheal epithelial cells [17]. 
The possible role of C. pneumoniae in the pathogenesis of asthma has also been studied. 
Several studies have reported that C. pneumoniae infection is associated with exacerbation of 
asthma and stable asthma [7, 8]. Surprisingly, in the TELICAST study, about sixty percent of 
patients showing exacerbation of asthma were found to have C. pneumoniae [24]. We 
demonstrated that C. pneumoniae dose-dependently increased MUC5AC production at both 
the mRNA and protein levels. Considering that airway mucus hypersecretion is one of the 
pathogeneses of asthma, our study indicates that C. pneumoniae may cause exacerbation of 
asthma by producing airway mucin.  
NF-B has been shown to play an important role in mucin production in numerous studies. 
In this study, C. pneumoniae activated both p65 and p50. Although CAPE decreased C. 
pneumoniae-induced MUC5AC production, it did not suppress it completely. These findings 
suggest that NF-B is partly associated with the MUC5AC production in the airway 
epithelial cells after C. pneumoniae contact. NF-B is not the only transcription factor that 
up-regulates MUC5AC gene expression. The AP-1 transcription factor binding site and 
NF-B binding site are located in the upstream of the MUC5AC gene [25]. AP-1 may be also 
involved in MUC5AC gene expression after C. pneumoniae-stimulation. Furthermore, C. 
pneumoniae up-regulated ERK phosphorylation and C. pneumoniae-induced MUC5AC 
production was inhibited by PD98059 and U0126 pre-treatment. These findings suggest that 
the ERK pathway may be associated with C. pneumoniae–induced mucin production. Other 
MAPKs, such as p38 and JNK, were not involved in C. pneumoniae-induced MUC5AC 
production (data not shown).  
In this study, C. pneumoniae-induced MUC5AC production was suppressed by macrolides 
and ketolides. Azithromycin suppressed C. pneumoniae-induced MUCAC at mRNA level 
after 8 h stimulation as well as the other drugs but appeared to be less effective at protein 
level after 24 h stimulation than the others. This finding of azithromycin may reflect 
shortness of its effect. With regard to NF-B levels, although telithromycin markedly 
suppressed p65 and p50 activity, clarithromycin suppressed only p65 activity, despite 
showing similar effects as telithromycin with regard to MUC5AC mRNA and protein 
production. This indicates that p65 may play a more important role in MUC5AC production 
than p50. Azithromycin also decreased p65 activation when compared to positive controls, 
but there was no statistically significant difference in the results for protein levels. 
Differences in effectiveness among macrolides have also been observed in cytokine 
production in vivo [26]. The suppressive effects vary depending on their actions against 
upstream signal transduction or transcriptional factors.  
As mentioned above, each drug attenuated NF-B activation, but did not inhibit the 
phospho-ERK after C. pneumoniae stimulation. This indicates that macrolides and ketolides 
inhibit pathways between ERK and NF-B to interfere with C. pneumoniae-induced 
MUC5AC expression.  
Macrolides and telithromycin have recently attracted attention in the treatment of bronchial 
asthma. Additional therapy with clarithromycin in the treatment of severe bronchial asthma 
patients significantly improved quality-of-life scores with reducing airway concentrations of 
IL-8 and neutrophil numbers [27]. In patients with exacerbation of asthma, co-treatment with 
telithromycin improved symptom scores and lung functions [24]. The reasons for the clinical 
benefits of these drugs among asthma patients are not well understood. Although macrolides 
and ketolides have antibacterial activity against C. pneumoniae, we consider that the effects 
of drugs in our data are results of immunomodulatory effects because noninfectious C. 
pneumoniae EBs were used. Our results suggest that macrolides and ketolides attenuate 
excessive mucus production, which then alleviates asthma symptoms. Considering the role of 
C. pneumoniae in exacerbation of asthma, our results support such clinical benefits in these 
patients. 
In this study, we used these antibiotics at a concentration of 50 g/ml. The mean 
steady-state concentrations of these antibiotics in alveolar macrophages after oral 
administration are reported to reach over 300 g/ml [28, 29], while those in the epithelial 
lining fluid reached over 3 g/ml [28-30]. Therefore, the concentration of antibiotics used in 
this study may be attainable in clinical cases.  
In conclusion, C. pneumoniae up-regulates MUC5AC production in airway epithelial cells 
and macrolides and ketolide suppress this MUC5AC production by interfering with signal 
transduction. Because mucus hypersecretion is thought to be one of the mechanisms of C. 
pneumoniae-induced exacerbation of bronchial asthma, macrolide and ketolide antibiotics 
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Fig.. 1. Production and gene expression of MUC5AC protein after C. pneumoniae stimulation. 
Cells were stimulated with 0.1, 1.0 or 10 g/ml C. pneumoniae. As a control, cells were 
treated with culture medium alone. (A, B) After 24 hours of stimulation, protein levels were 
measured by ELISA and are given in terms of % above control (n = 4). C. pneumoniae 
dose-dependently increased MUC5AC production in the supernatant (A) and in the cell lysate 
(B). Data are expressed as the means ± S.D. (C) After 8 hours of stimulation, gene expression 
levels were measured by quantitative RT-PCR and were normalized against hPBGD (n = 3). 
C. pneumoniae dose-dependently increased MUC5AC gene expression, with a significant 




Fig. 2. Activation of NF-kB after stimulation with 10 g/ml C. pneumoniae for the indicated 
time periods (n = 3). (a and b) C. pneumoniae-induced p65 activation was observed after 20 
min and gradually increased within 60 min (A). Activated p50 was observed after 20 min and 
peaked at 40 min (B). Results are expressed as means ± SD. * indicates p < 0.05 and † 
indicates p < 0.01 versus results at 0 min. (C and D) Cells were pretreated with specific a 
NF-B inhibitor, CAPE, for 30 min. CAPE at 10 M suppressed MUC5AC production in the 
supernatant (C, p = 0.050 vs. stimulation alone) and in the cell lysate (D, p = 0.043 vs. 




Fig. 3. Phosphorylation of ERK after C. pneumoniae stimulation. (A) Cells were treated with 
10 g/ml C. pneumoniae for the indicated time periods. ERK and phospho-ERK were 
detected by Western blotting. Phospho-ERK was not seen initially, but appeared after 20 min. 
Data is representative of three separate experiments. (B and C) The effects of PD98059 and 
U0126, ERK inhibitors, on MUC5AC production were analyzed at the protein level by 
ELISA. PD98059 (50 M) and U0126 (10 M) markedly reduced MUC5AC production both 
in the supernatant (B) and in the cell lysate (C). † indicates p < 0.01 
 
 
Fig. 4. Effects of macrolide and ketolide antibiotics on MUC5AC production induced by C. 
pneumoniae. Cells were pretreated with drugs for 30 min and were then stimulated with 10 
g/ml C. pneumoniae for 24 h (n = 4). MUC5AC protein was analyzed by ELISA both in the 
supernatant (A, C and E) and in the cell lysate (B, D and F). Azithromycin (A and B), 
clarithromycin (C and D) and telithromycin (E and F) dose-dependently suppressed C. 
pneumoniae-induced MUC5AC production. At 50 g/ml, all of the drugs except 
azithromycin significantly decreased MUC5AC production when compared to stimulation 
alone in the cell lysate (p = 0.050). * indicates p < 0.05 and † indicates p < 0.01.  
 
 
Fig. 5. Effects of macrolide and ketolide antibiotics on MUC5AC gene expression induced by 
C. pneumoniae. Cells were pretreated with each drug at 50 g/ml for 30 min and were then 
stimulated by 10 g/ml of C. pneumoniae for 8 h (n = 5). Each drug significantly suppressed 
C. pneumoniae-induced MUC5AC gene expression. † indicates p < 0.01 versus stimulation 
alone. 
 
Fig. 6. Effects of macrolide and ketolide antibiotics on NF-B. Cells were pretreated with 
each drug at 50 g/ml for 30 min, and were then stimulated by C. pneumoniae for 60 min (n 
= 4). All drugs suppressed p65 activation (A), but only telithromycin suppressed p50 
activation (B). † indicates p < 0.01 vs. stimulation alone. 
 
 
Fig. 7. Effects of macrolide and ketolide antibiotics on ERK phosphorylation. Cells were 
stimulated with C. pneumoniae for 20 min after pretreatment with each drug. Equal amounts 
of protein were analyzed. Drugs did not affect the detection levels of phospho-ERK when 
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